Eurofins expands presence in discovery pharmacology with the acquisition of Pan Labs US
Pan Labs, a leading provider in early stage discovery services, offers an unmatched portfolio of more than 1,300 In Vitro and In Vivo pharmacology assays that enable science-driven selection at every stage of the drug discovery and development process. Pan Labs has over 150 highly qualified employees and USD 20m in annual revenues with most of the largest global pharmaceutical companies. Pan Labs' portfolio of services includes molecular and functional pharmacology, cellular services, and informatics analytics. Here is a brief summary of Pan Labs' extensive pharmacology profiling portfolio:
- 310 enzyme assays
- 210 radioligand binding assays
- 120 GPCR assays
- 95 cellular assays
- 110 tissue assays
- 185 in vivo models
- 85 anti-infective assays
- 45 tumor assays
- 252 human cell line assays
- 17 assay packages
For more information, please contact Jamie Baumgartner, PhD, President of Eurofins Pan Labs:
jamiebaumgartner@eurofins.com.
